Skip to main content
Equibles

Brian Chang

Analyst

J.P. Morgan

Equibles does not estimate personal net worth.

About Brian Chang

Brian Chang is recorded as Analyst at J.P. Morgan. Brian Chang has spoken on 11 earnings calls and 3 other investor events across 11 companies, most recently for Tango Therapeutics, Inc. on October 23, 2026. Those appearances were for Ascentage Pharma Group International (AAPG), Revolution Medicines, Inc. (RVMD), Ptc Therapeutics, Inc. (PTCT), Tango Therapeutics, Inc. (TNGX), Kyverna Therapeutics, Inc. (KYTX) and 6 other companies. The companies whose calls Brian Chang spoke on are classified in the Healthcare and Technology sectors.

Brian Chang on recent calls

“You know, just first, I wonder if you can comment a little bit more about the durability response here. the PFS curves looks a lot more stable than there are some RASP alone in the second line back in the RASP 302 study.”
Analyst — J.P. Morgan, Tango Therapeutics Conference Call ·
“Thanks for taking our questions this morning, and congrats on the impressive longer-term data updates here. You know, first, I'm curious if you can talk a little bit about the impact that Nipsel has on these attacks that you see in sick person syndrome.”
Analyst — J.P. Morgan, Kyverna SPS and MG Longer-term Follow-up Data Conference Call ·
“And Faisal and James, welcome to the team. Just to start off in China, can you talk about how we should think about the NRDL listing for specifically at least after class later this year?”
Analyst — J.P. Morgan, Ascentage Pharma 2026 Interim Results Presentation ·
“And Faisal and James, welcome to the team. Just to start off in China, can you talk about how we should think about the NRDL listing for specifically at least after class later this year?”
Analyst — J.P. Morgan, Earnings conference call (announced in 6-K) ·
“Just first on the EAP, can you talk about whether these patients are being recruited in the sites that have had prior direxin or acid experience? And you know that more than 90% of the requests have been accepted.”
Analyst — J.P. Morgan, Revolution Medicines, Inc. Q2 FY2026 Earnings Call ·

Affiliation history

  • J.P. Morgan

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity

Show 2 earlier activities